Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms


Introduction

Human lactotroph adenomas (prolactinomas) are the most frequent functioning pituitary tumors (1), but their pathogenesis remains elusive. The primary regulation of prolactin (PRL) secretion is mediated by the inhibitory effects of dopamine released from the median eminence of the hypothalamus and acting at the dopamine D2 receptor subtype (D2R) (2). Mice deficient in PRL receptors (PRLR) have previously been found in aged Prlr–/– males, but only microscopic adenomas were found in Drd2–/– male mice. Pharmacologic studies in Prlr–/– mice with D2R agonists and antagonists demonstrated a significant loss of endogenous dopamine tone, i.e., constitutive inhibitory signaling by the D2R, in the pituitary. However, Prlr–/– mice exhibited more profound hyperprolactinemia and larger tumors than did age-matched Drd2–/– mice, and there were additive effects in compound homozygous mutant male mice. In vitro, PRL treatment markedly inhibited the proliferation of wild-type female and male Drd2–/– lactotrophs, but had no effect on female Drd2–/– lactotrophs, suggesting a downregulation or desensitization of PRLR in the pituitary in response to chronic hyperprolactinemia. We conclude that PRL inhibits lactotrophs by two distinct mechanisms: (a) indirectly by activation of hypothalamic dopamine neurons and (b) directly within the pituitary in a dopamine-independent fashion.

The Journal of Clinical Investigation O 2002 | Volume 110 | Number 7

973

Received for publication May 10, 2002, and accepted in revised form August 7, 2002.

Address correspondence to: Malcolm Low, Vollum Institute L-474, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201-3098, USA. Phone: (503) 494-4672; Fax: (503) 494-4976; E-mail: low@OHSU.edu. Kathryn G. Schuff and Shane T. Hentges contributed equally to this work.

Conflict of interest: No conflict of interest has been declared.

Nonstandard abbreviations used: prolactin (PRL); dopamine D2 receptor (D2R); tyrosine hydroxylase (TH); PRL receptor (PRLR); growth hormone (GH); thyroid-stimulating hormone (TSH); follicle-stimulating hormone (FSH); luteinizing hormone (LH); adrenocorticotropic hormone (ACTH); 3,4-dihydroxyphenylalanine (DOPA); aromatic amino acid decarboxylase (AADC).

Hypothalamic dopamine inhibits pituitary prolactin secretion and proliferation of prolactin-producing lactotroph cells by activating lactotroph dopamine D2 receptors (D2Rs). Conversely, prolactin (PRL) stimulates hypothalamic dopamine neurons via PRL receptors (PRLRs) in a short-loop feedback circuit. We used Drd2–/– and Prlr–/– mutant mice to bypass this feedback and investigate possible dopamine-independent effects of PRL on lactotroph function. The absence of either receptor induced hyperprolactinemia and large prolactinomas in females. Small macroadenomas developed in aged Prlr–/– males, but only microscopic adenomas were found in Drd2–/– male mice. Pharmacologic studies in Prlr–/– mice with D2R agonists and antagonists demonstrated a significant loss of endogenous dopamine tone, i.e., constitutive inhibitory signaling by the D2R, in the pituitary. However, Prlr–/– mice exhibited more profound hyperprolactinemia and larger tumors than did age-matched Drd2–/– mice, and there were additive effects in compound homozygous mutant male mice. In vitro, PRL treatment markedly inhibited the proliferation of wild-type female and male Drd2–/– lactotrophs, but had no effect on female Drd2–/– lactotrophs, suggesting a downregulation or desensitization of PRLR in response to chronic hyperprolactinemia. We conclude that PRL inhibits lactotrophs by two distinct mechanisms: (a) indirectly by activation of hypothalamic dopamine neurons and (b) directly within the pituitary in a dopamine-independent fashion.


PRL stimulates hypothalamic dopamine neurons via PRL receptors (PRLRs) in a short-loop feedback circuit. We used Drd2–/– and Prlr–/– mutant mice to bypass this feedback and investigate possible dopamine-independent effects of PRL on lactotroph function. The absence of either receptor induced hyperprolactinemia and large prolactinomas in females. Small macroadenomas developed in aged Prlr–/– males, but only microscopic adenomas were found in Drd2–/– male mice. Pharmacologic studies in Prlr–/– mice with D2R agonists and antagonists demonstrated a significant loss of endogenous dopamine tone, i.e., constitutive inhibitory signaling by the D2R, in the pituitary. However, Prlr–/– mice exhibited more profound hyperprolactinemia and larger tumors than did age-matched Drd2–/– mice, and there were additive effects in compound homozygous mutant male mice. In vitro, PRL treatment markedly inhibited the proliferation of wild-type female and male Drd2–/– lactotrophs, but had no effect on female Drd2–/– lactotrophs, suggesting a downregulation or desensitization of PRLR in response to chronic hyperprolactinemia. We conclude that PRL inhibits lactotrophs by two distinct mechanisms: (a) indirectly by activation of hypothalamic dopamine neurons and (b) directly within the pituitary in a dopamine-independent fashion.


Received for publication May 10, 2002, and accepted in revised form August 7, 2002.

Address correspondence to: Malcolm Low, Vollum Institute L-474, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201-3098, USA. Phone: (503) 494-4672; Fax: (503) 494-4976; E-mail: low@OHSU.edu. Kathryn G. Schuff and Shane T. Hentges contributed equally to this work.

Conflict of interest: No conflict of interest has been declared.

Nonstandard abbreviations used: prolactin (PRL); dopamine D2 receptor (D2R); tyrosine hydroxylase (TH); PRL receptor (PRLR); growth hormone (GH); thyroid-stimulating hormone (TSH); follicle-stimulating hormone (FSH); luteinizing hormone (LH); adrenocorticotropic hormone (ACTH); 3,4-dihydroxyphenylalanine (DOPA); aromatic amino acid decarboxylase (AADC).

Hypothalamic dopamine inhibits pituitary prolactin secretion and proliferation of prolactin-producing lactotroph cells by activating lactotroph dopamine D2 receptors (D2Rs). Conversely, prolactin (PRL) stimulates hypothalamic dopamine neurons via PRL receptors (PRLRs) in a short-loop feedback circuit. We used Drd2–/– and Prlr–/– mutant mice to bypass this feedback and investigate possible dopamine-independent effects of PRL on lactotroph function. The absence of either receptor induced hyperprolactinemia and large prolactinomas in females. Small macroadenomas developed in aged Prlr–/– males, but only microscopic adenomas were found in Drd2–/– male mice. Pharmacologic studies in Prlr–/– mice with D2R agonists and antagonists demonstrated a significant loss of endogenous dopamine tone, i.e., constitutive inhibitory signaling by the D2R, in the pituitary. However, Prlr–/– mice exhibited more profound hyperprolactinemia and larger tumors than did age-matched Drd2–/– mice, and there were additive effects in compound homozygous mutant male mice. In vitro, PRL treatment markedly inhibited the proliferation of wild-type female and male Drd2–/– lactotrophs, but had no effect on female Drd2–/– lactotrophs, suggesting a downregulation or desensitization of PRLR in response to chronic hyperprolactinemia. We conclude that PRL inhibits lactotrophs by two distinct mechanisms: (a) indirectly by activation of hypothalamic dopamine neurons and (b) directly within the pituitary in a dopamine-independent fashion.


Received for publication May 10, 2002, and accepted in revised form August 7, 2002.

Address correspondence to: Malcolm Low, Vollum Institute L-474, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201-3098, USA. Phone: (503) 494-4672; Fax: (503) 494-4976; E-mail: low@OHSU.edu. Kathryn G. Schuff and Shane T. Hentges contributed equally to this work.

Conflict of interest: No conflict of interest has been declared.

Nonstandard abbreviations used: prolactin (PRL); dopamine D2 receptor (D2R); tyrosine hydroxylase (TH); PRL receptor (PRLR); growth hormone (GH); thyroid-stimulating hormone (TSH); follicle-stimulating hormone (FSH); luteinizing hormone (LH); adrenocorticotropic hormone (ACTH); 3,4-dihydroxyphenylalanine (DOPA); aromatic amino acid decarboxylase (AADC).
crossing PRL-deficient (Prlr−/−) mice with Drd2−/− mice, we were able to evaluate a possible contribution of dopamine-independent effects of PRL signaling on the control of PRL secretion and lactotroph growth.

**Methods**

Generation of receptor-deficient mice. Generation of Drd2−/− and Prlr−/− mice by gene targeting in embryonic stem cells has been previously described (3,30). Each receptor-deficient line of mice was independently backcrossed to inbred C57BL/6J mice for five or more generations to produce incipient congenic lines and reduce variability from gene epistasis. Because of impaired fertility, lactation (30,31), and maternal behavior (32) in Prlr−/− mice, a selective breeding strategy and inclusion of CD-1 foster mothers were used in the intercrosses to produce sibling cohorts of wild-type, Drd2−/−, Prlr−/−, and compound mutant (Drd2−/−, Prlr−/−) mice for these studies. All animal care practices and experimental procedures were approved by the Oregon Health & Science University Institutional Animal Care and Use Committee.

**Determination of serum PRL.** Serum was obtained under brief isoflurane anesthesia from a tail bleed and frozen at −80°C until analysis. PRL radioimmunoassay used mouse PRL (mPRL) reference preparation AFP6476C, mPRL AFP1077D for iodination, and antimiPRL antiserum AFP6476C, mPRL AFP1077D (provided by A.F. Parlow and the National Hormone and Peptide Program, Harbor-UCLA Medical Center, Torrance, California, USA). The assay was performed as directed, except that mPRL was iodinated with 3µCi chloramine-T (Sigma-Aldrich, St. Louis, Missouri, USA) per µg peptide and purified with Dowex 20-50 chloride mesh resin beads (Bio-Rad Laboratories Inc., Hercules, California, USA); approximately 20,000 cpm was added to each tube. Assay sensitivity was 15 ng/ml using 10-µl serum samples. Samples were analyzed in duplicate at multiple dilutions. For drug responses, basal serum was collected from 15-month-old male mice, then 5 mg/kg haloperidol (Ortho-McNeil Pharmaceutical, Raritan, New Jersey, USA) was administered intraperitoneally, and post-treatment serum samples were obtained 1 hour later.

**Histologic analyses.** Mice were sacrificed by decapitation at ages 6,12,14,or 18–21 months, and their pituitary glands were inspected visually with a dissecting microscope, weighed, and placed immediately in 10% buffered formalin. Paraffin-embedded sections 4–5 µm thick were stained with hematoxylin and eosin or the Gordon-Sweet silver method for reticulin matrix. Immunohistochemical staining to identify adenohypophyseal hormones was performed using the streptavidin-biotin peroxidase technique. Primary antisera directed against rat pituitary hormones were used at the following dilutions: growth hormone (GH), 1:2,500; PRL, 1:2,500; thyroid-stimulating hormone (TSH-β), 1:3,000; follicle-stimulating hormone-β (FSH-β), 1:600; luteinizing hormone-β (LH-β), 1:2,500 (all provided by A.F. Parlow and the National Hormone and Peptide Program); and prediluted adrenocorticotropic hormone (ACTH), further diluted 1:20 (DAKO Corp., Carpinteria, California, USA). The gene expression was evaluated by in situ hybridization. Mice were sacrificed by decapitation, and brains were removed and snap-frozen in isopentane over dry ice and stored at −80°C. Ten-micrometer sections were cut on a cryostat and thaw-mounted onto gelatin-coated slides. TH mRNA was detected by hybridization at 60°C with 20 million cpm/ml of a 35S-UTP-labeled antisense riboprobe (provided by E. Lewis, Department of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, Oregon, USA). The slides were exposed to NBT2 emulsion (Eastman Kodak, Rochester, New York, USA) for 15 days, developed, and counterstained with neutral red. Digital images were captured using both bright- and dark-field illumination on a Leica research microscope (Leica Microsystems Inc., Deerfield, Illinois, USA). TH activity was estimated by the measurement of 3,4-dihydroxyphenylalanine (DOPA) accumulation after inhibition of aromatic amino acid decarboxylase (AADC) by m-hydroxybenzylhydrazine dihydrochloride (NSD 1015; Sigma-Aldrich). Briefly, mice were sacrificed by decapitation 30 minutes after an intraperitoneal injection of 100 mg/kg NSD 1015. Whole hypothalamic blocks and a portion of dorsal striatum were snap-frozen in isopentane on dry ice and stored at −80°C until analyzed. Hypothalami were sonicated in 20 volumes and striata in 50 volumes of homogenization solution and subjected to HPLC and electrochemical detection of DOPA as previously described (33).

**Primary cultures of anterior pituitary cells.** Anterior pituitary glands were collected from randomly cycling C57BL/6J mice and placed into ice-cold HBSS (Sigma-Aldrich) and dissociated enzymatically in HBSS containing collagenase, deoxyribonuclease, and BSA as described previously (34). Cells were plated at 250,000 cells/well on poly-l-lysine–coated glass coverslips in 24-well plates in DMEM/Ham’s F12 medium (1:1; Sigma-Aldrich) containing 50 U/ml penicillin G, 50 µg/ml streptomycin, and 10% FBS for 24 hours. The next day, 24 hours prior to PRL treatment, the medium was replaced with DMEM/F12 supplemented with Serum Replacement 2 (Sigma-Aldrich). For the 48-hour PRL treatment, the medium was replaced with DMEM/F12/Serum Replacement 2 containing recombinant mPRL (0–10 µg/ml; provided by A.F. Parlow and the National Hormone and Peptide Program). The media and treatment were changed at 24 hours, and 0.1 mM bromodeoxyuridine (BrdU; Sigma-Aldrich) was added for the last 12 hours of PRL treatment.

**Lactotroph cell proliferation.** Lactotroph cell proliferation was determined by identifying the cells that displayed immunoreactivity for both BrdU and PRL. After
treatment with mPRL and BrdU as above, cells were washed and fixed in 99% ice-cold ethanol and processed for immunofluorescence. The mouse monoclonal BrdU antibody (1:200; Becton Dickinson Immunocytotherapy Systems, San Jose, California, USA) and rabbit polyclonal mouse-specific PRL antibody (1:3,000; gift of F. Talamantes, Biology, University of California at Santa Cruz, Santa Cruz, California, USA) were detected with goat anti-mouse FITC-conjugated secondary antibodies (1:200; BioSource International, Camarillo, California, USA) and goat anti-rabbit rhodamine-conjugated secondary antibodies (1:200; American Qualex, San Clemente, California, USA). Cell nuclei were fluorescently labeled with Hoechst 33258 (Sigma-Aldrich). Cells immunoreactive for both BrdU and PRL were counted as dividing lactotrophs. Cell counts were made at 20× magnification on a Leica epifluorescence microscope. An investigator blind to the treatment and genotype counted five random areas in each coverslip, approximately 250 cells/area. Six to eight coverslips per treatment from three separate cultures were evaluated for each genotype.

Statistical analyses. Statistical analyses were performed using StatView statistical analysis software (SAS Institute Inc., Cary, North Carolina, USA). For comparisons within a genotype before and after drug treatment, one-tailed paired Student t tests were used because of the well-described direction of change. For comparisons among multiple genotypes, ANOVA was used. Post hoc analyses were by the Fisher post hoc test. All data are presented as mean ± SEM. P values less than 0.05 were considered significant.

Results

Hyperprolactinemia and pituitary pathology. Serum PRL increased exponentially with age in Drd2−/− mice, Prlr−/− mice, and compound receptor-deficient (Drd2−/−, Prlr−/−) mice (Figure 1, a and b). Levels were more markedly elevated in mutant females than males at all timepoints. In addition, there was earlier and more severe hyperprolactinemia in both sexes of Prlr−/− mice than in Drd2−/− mice, and additive effects of the combined mutations were apparent at both 12 and 18 months of age in males (Figure 1b).

Similar to our previous observations in Drd2−/− mice (3, 4), pituitary glands in Prlr−/− mice were significantly enlarged compared with those in the wild type starting at 6 months, and continued to increase in size in the older groups of female and male mice (Figure 1, c and d). However, at 6 months, the female Prlr−/− pituitary glands already exhibited distinct lactotroph hyperplasia (data not shown), a histological feature delayed until 10–12 months in female Drd2−/− mice (3). The pituitary glands of 14-month-old female Prlr−/− and compound receptor-mutant mice contained massive, multifocal tumors histologically similar to, though significantly larger than, those observed in female Drd2−/− mice of the same age. Histopathology of these tumors demonstrated that they were all monohormonal lactotroph adenomas characterized by extensive breakdown of the reticulin network, peliosis, and enlarged, pleomorphic nuclei with numerous mitotic figures (Figure 2). Hyperplased perinuclear Golgi networks were observed, indicating a hypersecretory state similar to that observed in human prolactinomas. Immunostaining

Figure 1

Hyperprolactinemia and pituitary enlargement in Drd2−/− and Prlr−/− mice. Serum PRL increased with age in both female (a) and male (b) Drd2−/− and Prlr−/− mice and was more marked in Prlr−/− mice. Deficiency of both receptors produced an additive effect on hyperprolactinemia in male mice. Prlr−/− mice of both sexes developed hyperprolactinemia at younger ages than did Drd2−/− mice. P < 0.005 for ANOVA of main effect of genotype at all timepoints. *P < 0.05 for pairwise comparisons by the Fisher post hoc test. n = 6–22 for ages 8 weeks and 6 months, and n = 4–8 for ages 12 months and older. (c) Female Drd2−/− mice and Prlr−/− mice had slightly enlarged pituitary glands at 6 months and massively enlarged glands at 14 months (10- to 20-fold greater than wild-type). (d) Moderate pituitary enlargement occurred only at 18–21 months in Prlr−/− and compound homozygous mutant male mice. P < 0.001 for ANOVA of main effect of genotype for females at 14 months and males at 18–21 months. *P < 0.05 for pairwise comparisons using the Fisher post hoc test; n = 3–4 for 6-month-old females and 12-month-old males (except n = 1 for Prlr−/− male and n = 2 for Drd2−/− males); n = 5–7 for 14-month-old females and 18- to 21-month-old males.
for GH, LH-β, ESH-β, TSH-β, and ACTH was negative in the adenomas (data not shown). Male Prlr-/- and compound receptor-deficient (Drd2-/-, Prlr-/-) mice developed smaller macroadenomas at 18–21 months, with an additive effect in mice with the compound mutation (Figure 1d). Similar histological characteristics were observed in these tumors (data not shown).

**Pharmacologic evaluation of hypothalamic dopamine.** We evaluated and compared the effect of the loss of PRL or dopamine signaling on hypothalamic dopamine neuron function in Drd2-/- and Prlr-/- mice and compound receptor-deficient (Drd2-/-, Prlr-/-) mice by three approaches: pharmacologic challenge with a D2R agonist and antagonist followed by measurement of serum PRL; in situ hybridization of mRNA for TH (the rate-limiting enzyme in the synthesis of dopamine); and assessment of TH activity by the quantitation of DOPA after inhibition of AADC. Only male mice were used for these experiments because of the early tumor development observed in female receptor mutant mice and consequent secondary distortion of the overlying stalk/median eminence and basal hypothalamus.

Wild-type male mice had low basal levels of serum PRL, which demonstrated a nonsignificant trend to reduction by the D2R agonist bromocriptine (Figure 3a), but serum PRL levels were significantly increased by the D2R antagonist haloperidol (Figure 3b), illustrating the dopamine inhibitory tone normally present on lactotrophs. Drd2-/- and compound mutant (Drd2-/-, Prlr-/-) mice exhibited no response to either drug, as expected from the absence of D2R. In contrast, Prlr-/- mice demonstrated an average 85% decline in serum PRL 1 hour after bromocriptine treatment (Figure 3a) and no response to haloperidol (Figure 3b), indicating the presence of functional D2R on lactotrophs and low endogenous dopamine tone in the pituitary of these mice.

**Hypothalamic TH expression.** The loss of dopamine tone in the pituitaries of Prlr-/- mice could be due to developmental reductions in the number of hypothalamic dopaminergic neurons (35) or decreased function of the neurons. We therefore performed in situ hybridization to detect TH mRNA in hypothalamic neuronal soma of male mice. Compared with levels in wild-type mice (Figure 4, a and d), levels of TH mRNA were qualitatively increased in the arcuate nucleus of Drd2-/- mice (Figure 4, b and e). In contrast, arcuate nucleus TH mRNA levels appeared decreased but clearly still evident in Prlr-/- mice (Figure 4, c and f). TH mRNA levels in dopamin-
...ergic neurons not regulated by PRL, such as the zona incerta (data not shown) and ventral tegmental area/substantia nigra, were comparable in Drd2+/− mice, Prlr+/− mice, and wild-type mice (Figure 4, g–i).

Hypothalamic dopamine synthesis. To estimate changes in the rate of dopamine synthesis resulting from decreased levels of TH or decreased activity of TH, DOPA content of brain tissues was measured after blockade of AADC. DOPA levels were significantly higher in striata from Drd2+/− mice than in striata from wild-type mice (Figure 4k), but were not significantly higher in the whole hypothalamus (Figure 4j) of Drd2+/− mice (although there was a trend toward an increase). In contrast, DOPA accumulation in the striatum and hypothalamus of Prlr+/− mice was not significantly different from that in the wild type.

Effects of in vitro PRL treatment. Despite the pharmacologic and neurochemical evidence of reduced tubero-hypophyseal dopamine tone in Prlr+/− mice, the phenotypic differences between Prlr+/− and Drd2+/− mice and additive effects of the combined mutations in males on serum PRL levels and pituitary size suggest that PRL and PRLR have additional dopamine-independent effects on lactotroph function. To determine whether there are direct pituitary effects of PRL on lactotroph growth, we assessed lactotroph proliferation in vitro by culturing dispersed pituitary cells from 10- to 12-month-old wild-type and Drd2+/− mice in the presence of recombinant mPRL in doses of 0.1–10 µg/ml (Figure 5). Absolute numbers of proliferating lactotrophs from wild-type males were too low to reliably quantitate. PRL treatment reduced the number of PRL-immunoreactive lactotrophs incorporating BrdU by 75% in pituitary cultures from wild-type female mice (Figure 5a). In contrast, there was no reduction in the number of proliferating lactotrophs in cultures of pituitaries from Drd2+/− female mice (Figure 5b), which in vivo already demonstrate marked hyperprolactinemia, lactotroph hyperplasia, and adenomas at this age. An in vivo BrdU labeling experiment performed in 6-month-old mice (data not shown) revealed a 5% labeling index of lactotrophs from Drd2+/− females, similar to the in vitro results; the figure was only 0.75% in wild-type females, indicating that the much higher basal index of wild-type lactotrophs in primary culture conditions is likely due to the acute loss of dopamine inhibition (2). Unlike the response in female Drd2+/− mice, PRL reduced the number of proliferating lactotrophs by 73% in cultures from male Drd2+/− mice (Figure 5c), which have only very modest hyperprolactinemia compared with the females (3, 4).

Discussion

Although the finding of hyperprolactinemia in Prlr+/− mice could be predicted based on the known feedback loop of PRL on hypothalamic dopaminergic neurons, the finding of pituitary hyperplasia and adenoma formation was a surprise. Previously, both we (3) and another group (11) concluded from our original studies of Drd2+/− mice that PRL most likely functioned as a mitogen for lactotrophs. In the majority of tissues where it has been evaluated, PRL is mitogenic (14–25), with only a few tissues demonstrating an antiproliferative role (26–29). However, we show here that in Prlr+/− mice, there are two factors contributing to the release of the lactotroph from its usual secretory and proliferative controls: a decrease in the normally inhibitory dopaminergic control and a second, direct effect at the level of the pituitary that is most consistent with an antiproliferative action of PRL on lactotrophs.

We have demonstrated that a lack of PRLR signaling results in decreased hypothalamic dopamine tone. This was shown pharmacologically by the absence of antagonizable dopamine action in male mice. The finding of an acute decline in serum PRL after bromocriptine treatment demonstrated that D2R signaling was intact in Prlr+/− mice, but the complete lack of response to the antagonist haloperidol suggests that dopaminergic input to the pituitary gland was very low, despite the marked hyperprolactinemia in these mice.

There are several possible, and not mutually exclusive, mechanisms that must be considered to explain the low levels of tuberoinfundibular dopamine in the Prlr+/− mice. These include the loss of the hypothalamic neuronal populations responsible for dopaminergic input to the pituitary, decreased levels or activity of TH (the rate-limiting enzyme in dopamine synthesis), and decreased neuronal activity of these hypothalamic neurons. Experiments with Snell dwarf mice indicated a requirement for PRL early in development to promote the normal survival and differentiation of the tuberoinfundibular dopaminergic neurons (35). However, subsequent studies of PRL peptide–deficient mice indicated that a lack of PRL predominantly affected the function...
and not the survival of dopaminergic neurons in the hypothalamus (36). Consistent with these later data, arcuate TH mRNA levels in the Prlr–/– mice were decreased but still present in a normal distribution in our study and were quantitatively normal in another (37), indicating grossly normal development of hypothalamic dopamine neurons. The reduction in levels of TH mRNA is consistent with PRL’s known positive regulatory feedback effects on transcription of the TH gene. Whether the decreased mRNA levels resulted in decreased amounts of TH enzyme, and whether there were additional changes in TH activity (mediated for example by changes in phosphorylation), was evaluated by measuring DOPA accumulation after blockade of AADC by NSD 1015. An increase in DOPA after NSD 1015 treatment has been shown to correlate with the activity of TH and with dopaminergic neuronal activity (38). As a control for the pharmacologic treatments, DOPA levels were measured and found to be significantly higher in striata from Drd2–/– mice than in striata from wild-type mice. This finding is consistent with increased TH activity secondary to the absence of inhibitory D2R autoreceptors from the mesostriatal dopamine neurons. However, DOPA levels also tended to be higher in the whole hypothalamus of Drd2–/– mice. Because the A12 tuberoinfundibular dopamine neurons do not normally express dopamine autoreceptors (38), we believe TH mRNA and DOPA accumulation in the hypothalamus of Drd2–/– mice tended to be higher due to increased PRL stimulation of these neurons (2, 5, 7). Notably, in other models of chronic hyperprolactinemia, exposure of tuberoinfundibular dopamine neurons to very high levels of PRL for extended periods of time abrogates the increase in dopaminergic activity of those neurons (39). This may explain why statistically significant changes were not seen in the current study.

In contrast, DOPA accumulation in neither striatum nor hypothalamus of Prlr–/– mice was significantly different from that in the wild type. It is likely that the low baseline levels of dopamine synthesis in male mice in combination with the presence of contaminating non-PRL-regulated catecholaminergic terminals present in the hypothalamic samples precluded detection of any reduction in DOPA accumulation in the hypothalamus of Prlr–/– mice. The arcuate nucleus has also been demonstrated to contain a substantial population of neurons that express TH but not AADC, and therefore normally synthesize L-DOPA as an end product; the accumulation of this L-DOPA would not be directly affected by the inhibition of AADC (40). Clearly, however, the loss of PRL signaling on hypothalamic dopamine neurons does not entirely explain the phenotypes observed in the two single-knockout mutants. Specifically, hyperprolactinemia has an earlier onset in both sexes of Prlr–/– mice than in Drd2–/– mice and is more severe in Prlr–/– mice than in Drd2–/– mice at

**Figure 4**

TH expression and activity. (a–i) In situ hybridization for TH mRNA; dark-field (a–c and g–i) and bright-field (d–f) microscopy. (a and d) Wild-type male mice express TH mRNA in the arcuate nucleus. TH mRNA is increased in Drd2–/– mice (b and e) and appears to be decreased, though clearly still evident, in Prlr–/– mice (c and f). Note comparable levels of TH mRNA in the ventral tegmental area and substantia nigra among the three genotypes: wild type (g), Drd2–/– (h), and Prlr–/– (i). Two or three mice per group were evaluated. (j) Hypothalamic and (k) striatal content of DOPA after NSD 1015 treatment. Striatal DOPA is significantly increased, and hypothalamic DOPA shows a similar trend in Drd2–/– mice, consistent with increased TH activity in dopamine neuronal terminals. DOPA levels did not differ between Prlr–/– and wild-type mice in either brain area. Scale bar represents 250 µm. Comparison was by ANOVA and Fisher post hoc test. *P < 0.05 compared with both other groups; n = 4–7.
several timepoints. Furthermore, in males there is an additive effect of the compound double knockout (Drd2<sup>−/−</sup>, Prlr<sup>−/−</sup>) with regard to both the degree of hyperprolactinemia at various timepoints and the size of pituitary adenoma formation. These differences in phenotype suggest that despite the evidence of reduced dopaminergic input from the experiments discussed above, there must be an additional mechanism for PRL in regulating lactotroph function.

A direct effect of PRL on the pituitary, and possibly even a specific direct effect on lactotrophs, is plausible. PRLRs have been localized to the pituitary gland in several species, including mouse (10, 11), but specifically identified on lactotrophs in only two species thus far—rat and human (12, 13). Our in vitro experiments present evidence of PRL action directly on mouse pituitary cells. Interestingly, PRL was observed to have an inhibitory effect on the proliferation of wild-type female lactotrophs. This effect appears to be completely independent of dopamine, as this in vitro model uses cultured pituitary cells grown in dopamine-free media. In addition, there was a similar inhibitory effect in pituitary cultures from male Drd2<sup>−/−</sup> mice. The lack of response in cultures from female Drd2<sup>−/−</sup> mice, but persistent response in cultures from male Drd2<sup>−/−</sup> mice, suggests that the antecedent hyperprolactinemia in the females downregulates the response to further PRL signaling. This is similar to other models of chronic hyperprolactinemia in which there is loss of the normal response of tuberoinfundibular dopaminergic neurons to PRL (39). Indeed, there is evidence that in other tissues PRL regulates its own receptor, with downregulation observed at extremely high concentrations, although there does not appear to be a consistent PRL level at which this downregulation occurs (41–43). The dichotomous response we observed appeared to occur with preceding serum PRL levels of approximately 500 ng/ml or greater. This level also represents a cutoff that separates the transition from lactotroph hyperplasia to adenoma in female Drd2<sup>−/−</sup> mice (3, 4) and distinguishes the microscopic adenomas of male Drd2<sup>−/−</sup> mice from the macroadenomas of male Prlr<sup>−/−</sup> mice and compound mutant Drd2<sup>−/−</sup>, Prlr<sup>−/−</sup> mice.

The inhibitory growth response of lactotrophs to PRL is quite different from the proliferative effect exhibited in nonpituitary cell types (14–19, 21–25), in human prolactinoma cells (44), and in a transformed rat lactotroph cell line (20). It is, however, consistent with models of PRL effects on EGF and TGF-α signaling cascades. Quijano and Sheffield demonstrated that PRL can decrease the growth-promoting action of EGF by increasing threonine phosphorylation and decreasing tyrosine phosphorylation of EGFR (45). Therefore, it may be that PRL exerts an inhibitory effect on lactotroph growth by limiting the actions of growth factors.

It was not possible in our experimental model to determine whether the inhibitory response to PRL was due to a direct action on lactotrophs or instead was mediated by juxtacrine or paracrine involvement of another anterior pituitary cell type. Possible mediation by one or more of the many other modulators of PRL secretion and lactotroph proliferation also cannot be ruled out. Evidence of both autocrine and paracrine regulation of lactotroph growth exists for TGF-β (46), EGF (47), galanin (48), and many other factors. Thus, there is abundant evidence for local pituitary control of lactotroph proliferation.

Using the genetic models of Drd2<sup>−/−</sup> and Prlr<sup>−/−</sup> mice, we have provided new evidence that PRL is the major physiological regulator of tuberoinfundibular dopamine tone and that PRLR signaling is necessary to maintain functionally relevant levels of dopamine release into the hypophysial portal-venous circulation. However, the unanticipated phenotypic differences between Drd2<sup>−/−</sup> and Prlr<sup>−/−</sup> mice, and the additive or possibly synergistic effects of the two mutations on lactotroph function in male mice, indicate an additional dopamine-independent role for PRL in the inhibition of PRL secretion and lactotroph growth. We demonstrated a profound in vitro inhibitory effect of PRL on lactotroph proliferation in primary mouse pituitary cells.

Figure 5
Effect of PRL treatment on lactotroph proliferation in primary pituitary cultures. Primary cultures were treated with increasing concentrations of rPRL. The proliferative index was calculated as the percentage of cells demonstrating immunoreactivity for both PRL and BrdU relative to the total number of PRL-immunoreactive cells. (a) PRL treatment reduced the proliferative index by a maximum of 75% in pituitary cultures from wild-type female mice. (b) PRL treatment had no effect on the lactotroph proliferative index in cultures from Drd2<sup>−/−</sup> female mice. (c) PRL treatment reduced the proliferative index by a maximum of 73% in pituitary cultures from Drd2<sup>−/−</sup> male mice. *P < 0.001 for ANOVA of main effect of PRL treatment for wild-type female and Drd2<sup>−/−</sup> male pituitary cultures. *P < 0.001 compared with control medium without recombinant PRL by Fisher post hoc test.
cultures, mediated either directly on lactotrophs or by paracrine or juxtacrine mechanisms through other pituitary cells. Growth inhibition was diminished when there was pronounced preceding hyperprolactinemia in vivo, indicating that a loss of growth inhibition by PRL may precede or accompany adenoma formation.

Maximal growth of pituitary tumors and hyperprolactinemia in the mice was observed only when lactotrophs were devoid of both D2R- and PRLR-mediated inhibition. This finding of synergistic effects in male Drd2+/– and Prlr+/– mice suggests possible implications for the pathogenesis and management of invasive lactotroph macroadenomas in humans. Furthermore, the finding of such a profound pituitary phenotype of massive lactotroph adenomas in Prlr+/– mice argues for evaluation of PRLR defects or PRLR signaling defects as a potential etiology of human macroprolactinomas. To date there are very few studies that have analyzed PRLR expression in prolactinomas (13, 49), and we are unaware of any studies assessing PRLR binding specifically to the plasma membrane in hyperprolactinemic states. Rather than altering receptor expression, prolonged hyperprolactinemia could alter PRLR signaling; such an evaluation has not yet been performed. Our data indicate the importance of determining specific functions and deficits in PRL signaling under hyperprolactinemic conditions. Such findings could have significant implications for understanding the etiology and progression of these tumors and perhaps for providing additional targets for pharmacologic intervention to complement D2R agonists.

Acknowledgments
We thank James Wessel and Kelvin So for technical assistance. This work was supported by NIH grants K08 DK-02477 (K.G. Schuff), T32 DK-07674 (S.T. Hengtes), T32 DA-07262 (M.A. Kelly), R01 EY-04864 (P.M. Iuvone), and P01 DK-55819 (M.J. Low), and by a grant from the Institut National de la Santé et de la Recherche Médicale (P.A. Kelly).

References